"Improved drug discovery platforms" is Daphnia Labs's model, and it's not just us, it includes lots of tech-enabled biotech startups (Recursion, BioAge, Verge Genomics, etc.) In Silicon Valley, these are success stories. In pharma as a whole, they're seen as speculative.
-
Show this thread
-
Once B-stage discovery-platform-driven companies start to show impressive clinical results, I think that'll validate the business model. But to actually give the platform a chance to succeed, founders need to keep enough control, or get enough buy-in from leadership/investors,
1 reply 0 retweets 2 likesShow this thread
to actually commit to the platform-driven model all the way into the clinic, instead of pivoting away too early. And that will require some initiative and strategy.
9:20 AM - 1 Jun 2019
0 replies
0 retweets
1 like
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.